Syngene International Limited (NSE:SYNGENE)
India
· Delayed Price · Currency is INR | Market Cap | 291.41B |
| Revenue (ttm) | 35.41B |
| Net Income (ttm) | 5.02B |
| Shares Out | 401.28M |
| EPS (ttm) | 12.48 |
| PE Ratio | 58.17 |
| Forward PE | 49.74 |
| Dividend | 1.25 (0.17%) |
| Ex-Dividend Date | Jun 28, 2024 |
| Volume | 547,825 |
| Average Volume | 666,221 |
| Open | 724.00 |
| Previous Close | 719.55 |
| Day's Range | 716.30 - 731.80 |
| 52-Week Range | 607.65 - 960.60 |
| Beta | 0.56 |
| RSI | 56.59 |
| Earnings Date | Apr 24, 2025 |
About Syngene International
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, prot... [Read more]
Financial Performance
In 2023, Syngene International's revenue was 34.89 billion, an increase of 9.26% compared to the previous year's 31.93 billion. Earnings were 5.10 billion, an increase of 9.82%.
Financial StatementsNews
Syngene International shares down 2.50% after USFDA issues Form 483 with five observations
Shares of Syngene International Ltd. fell nearly 2% in early trade on February 24 following an update on the USFDA inspection at its Bengaluru facility. The pharmaceutical contract research and manufa...
Suven Pharmaceuticals shares surge 12% as Macquarie initiates ‘Outperform’ rating with target price of Rs 1,500, estimating 29.9% upside potential
Shares of Suven Pharmaceuticals Ltd soared 12% today after Macquarie Equity Research initiated an ‘Outperform’ rating on multiple contract research, development, and manufacturing (CRDMO) companies, i...
Macquarie initiates Outperform call on Syngene International, Suven Pharma, Divi’s Lab, Blue Jet Healthcare
Macquarie has initiated coverage on India’s contract research, development, and manufacturing organization (CRDMO) sector, highlighting secular growth trends and regulatory tailwinds that are set to d...
Syngene International appoints Peter Bains as the CEO Designate of the company
Syngene International Limited has officially announced leadership changes as Jonathan Hunt steps down from his role as MD & CEO as well as from the Board of Directors. This transition is effective imm...
Syngene International shares fall nearly 6% on weak FY25 guidance and demand recovery delay
Shares of Syngene International Ltd, a subsidiary of Biocon, fell 5.91% to ₹796.90 on Friday, January 24, 2025, following a disappointing FY25 guidance update and concerns over delayed demand recovery...
Syngene shares surge after 2% equity worth Rs 706 crore changes hands in block deal
Syngene International witnessed a significant trading volume today as 82.2 lakh shares, representing 2% of the company’s equity, were exchanged via a block deal valued at ₹706 crore. The shares were t...
Syngene International’s market cap decreases by Rs 760 crore as shares drop 2.19% today – Know More
Shares of Syngene International Limited fell by 2.19% today, closing at Rs 842.75, down from the previous close of Rs 861.60. The decline led to an estimated market capitalization loss of Rs 760 crore...